<DOC>
	<DOC>NCT00790556</DOC>
	<brief_summary>A 2-period crossover study to assess the safety, tolerability and glucose-lowering effects of MK8245.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)</brief_title>
	<detailed_description>Hypothesis: Multiple doses of MK-8245 are sufficiently safe and well tolerated in patients with Type 2 diabetes based on an assessment of clinical and laboratory adverse experiences (AEs), to permit continued clinical investigation.</detailed_description>
	<criteria>Subject has a diagnosis of Type 2 Diabetes and is being treated with diet and exercise alone or a single oral antihyperglycemic agent Subject is willing to follow the weightmaintaining diet and exercise program or equivalent beginning 4 weeks before receiving study drug, throughout the study and until the post study visit Subject has been a nonsmoker and/or has not used nicotinecontaining products for at least approximately 6 months Subject has a history of stroke, chronic seizures, or major neurological disorder Subject has a history of neoplastic disease (except nonmelanomatous skin carcinoma, carcinoma in situ of the cervix, other malignancies successfully treated at least 10 years prior to screening, or malignancies deemed highly unlikely to recur.) Subject has a history of Type 1 Diabetes Mellitus and/or history of ketoacidosis Subject has a history of contact lens use within approximately the previous 6 months Subject has been diagnosed with dry eye syndrome Subject has used lipidlowering therapies in the past 3 months (Subjects on a stable monotherapy dose of statins may be included) Subject has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks of starting in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>